- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01844674
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
March 16, 2017 updated by: Hoffmann-La Roche
A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
This open-label, multicenter, 3-period, fixed-sequence study will evaluate the effect of multiple oral doses of vemurafenib on the pharmacokinetics of a single oral dose of tizanidine in participants with BRAFV600 mutation-positive metastatic malignancies.
Participants will receive a single oral dose of tizanidine on Day 1, vemurafenib orally twice daily on Days 2 to 21, and tizanidine and vemurafenib on Day 22. Eligible participants will have the option to continue treatment with vemurafenib as part of an extension study (NCT01739764).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
RJ
-
Rio de Janeiro, RJ, Brazil, 20560-120
- Instituto Nacional do Cancer - INCA
-
-
RS
-
Ijui, RS, Brazil, 98700-000
- Hospital de Caridade de Ijui; Oncologia
-
Passo Fundo, RS, Brazil, 99010-260
- CITO - Centro Integrado de Terapia Onco-Hematológica - Hospital da Cidade de Passo Fundo
-
Porto Alegre, RS, Brazil, 90610-000
- Hospital Sao Lucas - PUCRS
-
-
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- CSSS champlain - Charles-Le Moyne
-
-
-
-
-
Nicosia, Cyprus, 2006
- Bank of Cyprus Oncology Center
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center.
-
-
-
-
California
-
Pleasant Hill, California, United States, 94523
- Diablo Valley Oncology and Hematology
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Health Systems
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults 18 to 70 years of age, inclusive
- Unresectable Stage IIIc or IV metastatic melanoma positive for the BRAFV600 mutation or other malignant tumor type which harbors a V600 activating mutation of BRAF, as determined by Cobas 4800 BRAFV600 Mutation Test or a DNA sequencing method
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- Life expectancy greater than or equal to (>/=) 12 weeks
- Participant has not consumed tobacco or nicotine-containing products for 42 days prior to first dose of study drug, and must agree to refrain from such products while on study
- Adequate hematologic, renal and liver function
Exclusion Criteria:
- Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Day 1
- History of or current clinically significant cardiac or pulmonary dysfunction, including current uncontrolled Grade >/= 2 hypertension or unstable angina
- Current dyspnea at rest due to complications of advanced malignancy or any requirement for supplemental oxygen
- Active central nervous system lesions (participants with radiographically unstable, symptomatic lesions)
- Participants with CYP1A2 gene mutation (-3113G->A), either in one or two alleles
- Allergy or hypersensitivity to vemurafenib or tizanidine formulations
- Current severe uncontrolled systemic disease
- Inability or unwillingness to swallow pills
- History of malabsorption or other condition that would interfere with enteral absorption of study treatment
- History of clinically significant liver disease (including cirrhosis), current alcohol abuse, or human immunodeficiency (HIV) infection requiring antiretroviral treatment, acquired immune deficiency syndrome (AIDS)-related illness, or active hepatitis B or C
- Pregnant or breastfeeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pharmacokinetic Population
All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
|
Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast >/= 10 hours.
Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Area under the concentration-time curve (AUC)
Time Frame: Pre-dose and up to 12 hours post-dose
|
Pre-dose and up to 12 hours post-dose
|
Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Maximum plasma concentration (Cmax)
Time Frame: Pre-dose and up to 12 hours post-dose
|
Pre-dose and up to 12 hours post-dose
|
Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Time to maximum plasma concentration (Tmax)
Time Frame: Pre-dose and up to 12 hours post-dose
|
Pre-dose and up to 12 hours post-dose
|
Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Terminal half-life (t1/2)
Time Frame: Pre-dose and up to 12 hours post-dose
|
Pre-dose and up to 12 hours post-dose
|
Pharmacokinetics of tizanidine under conditions of vemurafenib steady-state exposure: Apparent clearance (CL/F)
Time Frame: Pre-dose and up to 12 hours post-dose
|
Pre-dose and up to 12 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: Incidence, nature and severity of adverse events and serious adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0
Time Frame: Up to approximately 9 months
|
Up to approximately 9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 2, 2013
Primary Completion (Actual)
August 26, 2014
Study Completion (Actual)
August 26, 2014
Study Registration Dates
First Submitted
April 29, 2013
First Submitted That Met QC Criteria
April 29, 2013
First Posted (Estimate)
May 1, 2013
Study Record Updates
Last Update Posted (Actual)
March 20, 2017
Last Update Submitted That Met QC Criteria
March 16, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Antineoplastic Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Protein Kinase Inhibitors
- Anticonvulsants
- Neuromuscular Agents
- Muscle Relaxants, Central
- Vemurafenib
- Tizanidine
Other Study ID Numbers
- GO28396
- 2012-003705-94 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma, Neoplasms
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsUnited States, South Africa, Croatia, Brazil, Egypt
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsSpain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsBelgium, Spain, Germany, Netherlands, Finland
-
The Netherlands Cancer InstituteBristol-Myers SquibbActive, not recruitingMalignant Melanoma Stage IIIAustria, Netherlands, Australia, Sweden
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
Clinical Trials on Tizanidine
-
Second Affiliated Hospital, School of Medicine,...SICHUAN CREDIT PHARMACEUTICAL CO., LTD.Not yet recruitingMigraine Without Aura | Migraine With AuraChina
-
Teva GTCTerminated
-
Teva GTCCompleted
-
Teva GTCCompletedTraumatic Brain InjuryIsrael
-
Elan PharmaceuticalsCompletedStroke | Multiple Sclerosis | Muscle Spasticity | Spinal Cord InjuryUnited States
-
Acorda TherapeuticsSyneos HealthTerminatedSpasticity Due to Cerebral PalsyUnited States
-
Rothman Institute OrthopaedicsUnknownPain, PostoperativeUnited States
-
Sun Pharma Advanced Research Company LimitedWithdrawnAcute Muscle Pain
-
Indiana UniversityNational Institute of General Medical Sciences (NIGMS)RecruitingDrug-Drug InteractionUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting